Astellas Pharma
Search results
Jun 26, 2024 · Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
- Newsroom
Learn more about Takeda's latest press releases. This...
- Products
The work we do transforms lives, helping patients with...
- FLEXBUMIN 25% SOL 50 ML 24EA
If you are interested in ordering from Takeda's product...
- Newsroom
Jun 14, 2024 · OSAKA, Japan and CAMBRIDGE, Massachusetts, June 14, 2024 – Takeda ( TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in develo...
Jun 22, 2024 · Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia. June 24, 2024. Share. Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161.
- 2-ch?me-1-1 Nihonbashihonch?, Chuo City, 103-0023, Tokyo
Jun 11, 2024 · Takeda Invests 230 Million US Dollars in Expanding Production Capacity for Plasma-Derived Therapies at Los Angeles Manufacturing Site. June 11, 2024. Increased Production Capacity Resulting from the Expansion will Help to Serve More Patients with Rare, Chronic and Genetic Diseases, such as Immunodeficiencies and Bleeding Disorders.
Jun 15, 2024 · Takeda Pharmaceutical Co. signed an option agreement with Chinese drug developer Ascentage Pharma Group International for the development of a blood-cancer drug, as the Japanese drug maker ...
Jun 20, 2024 · From a single stall in an Osaka market to a global biopharmaceutical leader, we’ve always maintained a single set of values to guide our commitment to patients, our people, and the planet. And that has given us incredible stories to tell. The values we believe in. The people who live them.
Jun 14, 2024 · Ascentage Pharma is investigating olverembatinib in multiple clinical studies in several types of cancer. Olverembatinib has been granted orphan drug designation and Fast Track designation by the...
